KSV01 Injection for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

This study is testing KSV01 — a new CAR-T cell therapy where a patient's own immune cells are engineered in a lab to attack cancer — for people with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL), a type of blood cancer that has come back or stopped responding to treatment. **You may be eligible if...** - You are between 18 and 80 years old - You have confirmed B-cell NHL that has returned or is not responding to treatment - You are in reasonably good physical condition (ECOG score 0–1, KPS ≥70) - Your life expectancy is more than 3 months - You have adequate organ function based on blood tests **You may NOT be eligible if...** - You have active brain involvement from lymphoma - You have serious autoimmune disease or uncontrolled infections - You have had certain prior CAR-T or gene therapy treatments - Your heart, liver, or kidney function is too poor to safely receive the treatment Talk to your doctor to see if this trial is right for you.